MX2019005154A - Derivados de [1,2,4]triazol[1,5-a]pirimidina como inhibidores de pde2. - Google Patents
Derivados de [1,2,4]triazol[1,5-a]pirimidina como inhibidores de pde2.Info
- Publication number
- MX2019005154A MX2019005154A MX2019005154A MX2019005154A MX2019005154A MX 2019005154 A MX2019005154 A MX 2019005154A MX 2019005154 A MX2019005154 A MX 2019005154A MX 2019005154 A MX2019005154 A MX 2019005154A MX 2019005154 A MX2019005154 A MX 2019005154A
- Authority
- MX
- Mexico
- Prior art keywords
- triazolo
- pyrimidine derivatives
- pde2 inhibitors
- pde2
- compounds
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/08—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Psychiatry (AREA)
- Addiction (AREA)
- Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Epidemiology (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Abstract
La presente invencion se relaciona con nuevos derivados [1,2,4]triazol[1,5- a]pirimidin-ilo como inhibidores de la fosfodiesterasa 2 (PDE2); la invencion tambien esta dirigida a composiciones farmaceuticas que comprenden los compuestos, a procesos para preparar dichos compuestos y composiciones, y al uso de dichos compuestos y composiciones en la prevencion y el tratamiento de trastornos en los cuales esta involucrada la PDE2, tales como trastornos neurológicos y psiquiatricos.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP16196924 | 2016-11-02 | ||
PCT/EP2017/077910 WO2018083098A1 (en) | 2016-11-02 | 2017-10-31 | [1,2,4]triazolo[1,5-a]pyrimidine derivatives as pde2 inhibitors |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2019005154A true MX2019005154A (es) | 2019-06-20 |
Family
ID=57240919
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2019005154A MX2019005154A (es) | 2016-11-02 | 2017-10-31 | Derivados de [1,2,4]triazol[1,5-a]pirimidina como inhibidores de pde2. |
Country Status (18)
Country | Link |
---|---|
US (1) | US10947242B2 (es) |
EP (1) | EP3535267B1 (es) |
JP (1) | JP7076441B2 (es) |
KR (1) | KR20190070972A (es) |
CN (1) | CN109923116B (es) |
AR (1) | AR110026A1 (es) |
AU (1) | AU2017353310B2 (es) |
BR (1) | BR112019008404A2 (es) |
CA (1) | CA3041412A1 (es) |
EA (1) | EA039788B1 (es) |
ES (1) | ES2864131T3 (es) |
IL (1) | IL266305B (es) |
MX (1) | MX2019005154A (es) |
MY (1) | MY193511A (es) |
SG (1) | SG11201903892UA (es) |
TW (1) | TWI764950B (es) |
UA (1) | UA125302C2 (es) |
WO (1) | WO2018083098A1 (es) |
Families Citing this family (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
UA122423C2 (uk) | 2015-11-02 | 2020-11-10 | Янссен Фармацевтика Нв | [1,2,4]ТРИАЗОЛО[1,5-a]ПІРИМІДИН-7-ІЛЬНА СПОЛУКА |
KR20190071721A (ko) * | 2016-11-02 | 2019-06-24 | 얀센 파마슈티카 엔.브이. | Pde2 억제제로서의 [1,2,4]트리아졸로[1,5-a]피리미딘 화합물 |
MX2019005123A (es) | 2016-11-02 | 2019-06-20 | Janssen Pharmaceutica Nv | Compuestos de [1,2,4]triazolo[1,5-a]pirimidina como inhibidores de pde2. |
JP7076441B2 (ja) | 2016-11-02 | 2022-05-27 | ヤンセン ファーマシューティカ エヌ.ベー. | PDE2阻害剤としての[1,2,4]トリアゾロ[1,5-a]ピリミジン誘導体 |
WO2021257857A1 (en) | 2020-06-19 | 2021-12-23 | Incyte Corporation | Naphthyridinone compounds as jak2 v617f inhibitors |
US11753413B2 (en) | 2020-06-19 | 2023-09-12 | Incyte Corporation | Substituted pyrrolo[2,1-f][1,2,4]triazine compounds as JAK2 V617F inhibitors |
AU2021300429A1 (en) | 2020-07-02 | 2023-02-16 | Incyte Corporation | Tricyclic urea compounds as JAK2 V617F inhibitors |
WO2022006456A1 (en) | 2020-07-02 | 2022-01-06 | Incyte Corporation | Tricyclic pyridone compounds as jak2 v617f inhibitors |
US11661422B2 (en) | 2020-08-27 | 2023-05-30 | Incyte Corporation | Tricyclic urea compounds as JAK2 V617F inhibitors |
US11919908B2 (en) | 2020-12-21 | 2024-03-05 | Incyte Corporation | Substituted pyrrolo[2,3-d]pyrimidine compounds as JAK2 V617F inhibitors |
TW202302589A (zh) | 2021-02-25 | 2023-01-16 | 美商英塞特公司 | 作為jak2 v617f抑制劑之螺環內醯胺 |
Family Cites Families (44)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0591426A4 (en) | 1991-06-27 | 1996-08-21 | Univ Virginia Commonwealth | Sigma receptor ligands and the use thereof |
ZA99607B (en) | 1998-01-27 | 1999-07-27 | Rhone Poulenc Rorer Pharma | Substituted oxoazaheterocyclyl factor xa inhibitors. |
US6194410B1 (en) | 1998-03-11 | 2001-02-27 | Hoffman-La Roche Inc. | Pyrazolopyrimidine and pyrazolines and process for preparation thereof |
US20040014744A1 (en) | 2002-04-05 | 2004-01-22 | Fortuna Haviv | Substituted pyridines having antiangiogenic activity |
AU2003299145A1 (en) | 2002-10-03 | 2004-04-23 | Vertex Pharmaceuticals, Inc. | Piperazine and piperidine derivatives for treatment of neurological diseases |
WO2004108136A1 (en) | 2003-06-04 | 2004-12-16 | Vernalis (Cambridge) Limited | Triazolo `1 , 5-a!pyrimidines and their use in medicine |
EP1781659B1 (en) * | 2003-07-16 | 2008-11-05 | Janssen Pharmaceutica N.V. | Triazolopyrimidine derivatives as glycogen synthase kinase 3 inhibitors |
US7728025B2 (en) | 2003-12-29 | 2010-06-01 | Banyu Pharmaceutical Co., Ltd. | 2-heteroaryl-substituted benzimidazole derivative |
AR051092A1 (es) | 2004-09-20 | 2006-12-20 | Xenon Pharmaceuticals Inc | Derivados heterociclicos y su uso como inhibidores de la estearoil-coa |
CN101083992A (zh) | 2004-09-20 | 2007-12-05 | 泽农医药公司 | 抑制人硬脂酰CoA去饱和酶的哒嗪衍生物 |
DE602005023333D1 (de) | 2004-10-15 | 2010-10-14 | Takeda Pharmaceutical | Kinaseinhibitoren |
US7507842B2 (en) | 2005-08-12 | 2009-03-24 | Radiorx, Inc. | Cyclic nitro compounds, pharmaceutical compositions thereof and uses thereof |
WO2007113136A1 (de) | 2006-03-30 | 2007-10-11 | Basf Aktiengesellschaft | Verwendung von substituierten riazolopyrimidinen zur bekämpfung von phyto pathogenen schadpilzen |
JP2007332061A (ja) | 2006-06-14 | 2007-12-27 | Nippon Kayaku Co Ltd | 新規ピラゾロ[1,5−a]ピリミジン誘導体及びその用途 |
US8153803B2 (en) | 2006-07-18 | 2012-04-10 | The General Hospital Corporation | Compositions and methods for modulating sirtuin activity |
WO2008048914A1 (en) | 2006-10-17 | 2008-04-24 | Boehringer Ingelheim International Gmbh | Polycyclic compounds which modulate the cb2 receptor |
US8138168B1 (en) | 2007-09-26 | 2012-03-20 | Takeda Pharmaceutical Company Limited | Renin inhibitors |
GB0719803D0 (en) | 2007-10-10 | 2007-11-21 | Cancer Rec Tech Ltd | Therapeutic compounds and their use |
TWI481607B (zh) * | 2009-12-17 | 2015-04-21 | Lundbeck & Co As H | 作為pde10a酵素抑制劑的2-芳基咪唑衍生物 |
DK2835131T3 (en) * | 2010-12-14 | 2017-12-04 | Electrophoretics Ltd | Casein kinase 1 delta inhibitors (CK1 delta) |
SG192576A1 (en) | 2011-02-23 | 2013-09-30 | Pfizer | IMIDAZO[5,1-f][1,2,4]TRIAZINES FOR THE TREATMENT OF NEUROLOGICAL DISORDERS |
EA027418B1 (ru) | 2011-06-27 | 2017-07-31 | Янссен Фармацевтика Нв | ПРОИЗВОДНЫЕ 1-АРИЛ-4-МЕТИЛ[1,2,4]ТРИАЗОЛО[4,3-a]ХИНОКСАЛИНА, ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ НА ИХ ОСНОВЕ, СПОСОБЫ ПОЛУЧЕНИЯ И ПРИМЕНЕНИЯ ИХ, ПРОМЕЖУТОЧНЫЕ СОЕДИНЕНИЯ |
CA2849726A1 (en) | 2011-09-23 | 2013-03-28 | Advinus Therapeutics Limited | Amide compounds, compositions and applications thereof |
US9034882B2 (en) | 2012-03-05 | 2015-05-19 | Bristol-Myers Squibb Company | Inhibitors of human immunodeficiency virus replication |
HUE038786T2 (hu) | 2012-03-09 | 2018-11-28 | Lexicon Pharmaceuticals Inc | Pirazolo[1,5-a]pirimidin-alapú vegyületek, ezeket tartalmazó kompozíciók és eljárások alkalmazásukra |
JP6577479B2 (ja) | 2014-02-27 | 2019-09-18 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングMerck Patent Gesellschaft mit beschraenkter Haftung | Nav チャンネル阻害剤としてのヘテロ環化合物及びその使用 |
WO2015140051A1 (en) * | 2014-03-19 | 2015-09-24 | Boehringer Ingelheim International Gmbh | Heteroaryl sik inhibitors |
PL3597649T3 (pl) * | 2014-04-23 | 2022-04-04 | Dart Neuroscience Llc | Kompozycje zawierające podstawione związki [1,2,4]triazolo[1,5-a]pirymidyn-7-ylowe jako inhibitory pde2 |
TN2016000452A1 (en) * | 2014-04-25 | 2018-04-04 | Pfizer | Heteroaromatic compounds and their use as dopamine d1 ligands. |
CN105566321B (zh) | 2014-10-29 | 2020-04-21 | 广东东阳光药业有限公司 | 杂芳化合物及其在药物中的应用 |
EP3215508A1 (en) * | 2014-11-05 | 2017-09-13 | Dart NeuroScience (Cayman) Ltd. | Substituted 5-methyl-[1, 2, 4]triazolo [1,5-a) pyrimidin-2-amine compounds as pde2 inhibitors |
TWI530688B (zh) * | 2014-11-18 | 2016-04-21 | 彭顯智 | 製備微奈米探針設備及方法 |
WO2016107602A1 (zh) | 2015-01-01 | 2016-07-07 | 成都贝斯凯瑞生物科技有限公司 | 一类取代氮杂环衍生物及其应用 |
WO2016145614A1 (en) | 2015-03-17 | 2016-09-22 | Merck Sharp & Dohme Corp. | Triazolyl pyrimidinone compounds as pde2 inhibitors |
WO2017000277A1 (en) | 2015-07-01 | 2017-01-05 | Merck Sharp & Dohme Corp. | Substituted triazolo bicycliccompounds as pde2 inhibitors |
WO2017000276A1 (en) | 2015-07-01 | 2017-01-05 | Merck Sharp & Dohme Corp. | Bicyclic heterocyclic compounds as pde2 inhibitors |
US20180305334A1 (en) | 2015-10-14 | 2018-10-25 | Aquinnah Pharmaceuticals, Inc. | Compounds, compositions and methods of use against stress granules |
UA122423C2 (uk) * | 2015-11-02 | 2020-11-10 | Янссен Фармацевтика Нв | [1,2,4]ТРИАЗОЛО[1,5-a]ПІРИМІДИН-7-ІЛЬНА СПОЛУКА |
CN105898377A (zh) * | 2015-12-11 | 2016-08-24 | 乐视网信息技术(北京)股份有限公司 | 用户终端、服务器及弹幕加载方法、系统 |
WO2017157882A1 (en) | 2016-03-14 | 2017-09-21 | Université Catholique de Louvain | Serine biosynthetic pathway inhibitors |
KR20190071721A (ko) | 2016-11-02 | 2019-06-24 | 얀센 파마슈티카 엔.브이. | Pde2 억제제로서의 [1,2,4]트리아졸로[1,5-a]피리미딘 화합물 |
JP7076441B2 (ja) | 2016-11-02 | 2022-05-27 | ヤンセン ファーマシューティカ エヌ.ベー. | PDE2阻害剤としての[1,2,4]トリアゾロ[1,5-a]ピリミジン誘導体 |
MX2019005123A (es) | 2016-11-02 | 2019-06-20 | Janssen Pharmaceutica Nv | Compuestos de [1,2,4]triazolo[1,5-a]pirimidina como inhibidores de pde2. |
JP2020503300A (ja) | 2016-12-16 | 2020-01-30 | ヤンセン ファーマシューティカ エヌ.ベー. | 二環式oga阻害剤化合物 |
-
2017
- 2017-10-31 JP JP2019522892A patent/JP7076441B2/ja active Active
- 2017-10-31 EP EP17792066.7A patent/EP3535267B1/en active Active
- 2017-10-31 UA UAA201906027A patent/UA125302C2/uk unknown
- 2017-10-31 ES ES17792066T patent/ES2864131T3/es active Active
- 2017-10-31 TW TW106137541A patent/TWI764950B/zh not_active IP Right Cessation
- 2017-10-31 MY MYPI2019002499A patent/MY193511A/en unknown
- 2017-10-31 WO PCT/EP2017/077910 patent/WO2018083098A1/en active Application Filing
- 2017-10-31 SG SG11201903892UA patent/SG11201903892UA/en unknown
- 2017-10-31 US US16/346,730 patent/US10947242B2/en active Active
- 2017-10-31 AU AU2017353310A patent/AU2017353310B2/en not_active Ceased
- 2017-10-31 BR BR112019008404A patent/BR112019008404A2/pt active Search and Examination
- 2017-10-31 MX MX2019005154A patent/MX2019005154A/es unknown
- 2017-10-31 CA CA3041412A patent/CA3041412A1/en active Pending
- 2017-10-31 EA EA201991109A patent/EA039788B1/ru unknown
- 2017-10-31 CN CN201780067759.3A patent/CN109923116B/zh active Active
- 2017-10-31 KR KR1020197015232A patent/KR20190070972A/ko active IP Right Grant
- 2017-11-02 AR ARP170103037A patent/AR110026A1/es unknown
-
2019
- 2019-04-29 IL IL266305A patent/IL266305B/en unknown
Also Published As
Publication number | Publication date |
---|---|
US10947242B2 (en) | 2021-03-16 |
EP3535267A1 (en) | 2019-09-11 |
AU2017353310B2 (en) | 2021-08-12 |
EA039788B1 (ru) | 2022-03-14 |
CA3041412A1 (en) | 2018-05-11 |
ES2864131T3 (es) | 2021-10-13 |
CN109923116A (zh) | 2019-06-21 |
JP2019532985A (ja) | 2019-11-14 |
IL266305B (en) | 2021-10-31 |
TW201831486A (zh) | 2018-09-01 |
KR20190070972A (ko) | 2019-06-21 |
UA125302C2 (uk) | 2022-02-16 |
US20190276462A1 (en) | 2019-09-12 |
IL266305A (en) | 2019-06-30 |
BR112019008404A2 (pt) | 2019-09-17 |
JP7076441B2 (ja) | 2022-05-27 |
EP3535267B1 (en) | 2020-12-30 |
AR110026A1 (es) | 2019-02-13 |
CN109923116B (zh) | 2022-12-06 |
MY193511A (en) | 2022-10-17 |
WO2018083098A1 (en) | 2018-05-11 |
TWI764950B (zh) | 2022-05-21 |
SG11201903892UA (en) | 2019-05-30 |
EA201991109A1 (ru) | 2019-09-30 |
AU2017353310A1 (en) | 2019-05-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2019005154A (es) | Derivados de [1,2,4]triazol[1,5-a]pirimidina como inhibidores de pde2. | |
PH12018500944A1 (en) | [1,2,4]TRIAZOLO[1,5-a]PYRIMIDIN-7-YL COMPOUND | |
MX2019005115A (es) | Compuestos de [1,2,4]triazolo[1,5-a]pirimidina como inhibidores de pde2. | |
MX2019005123A (es) | Compuestos de [1,2,4]triazolo[1,5-a]pirimidina como inhibidores de pde2. | |
MY160305A (en) | Imidazo [1,2-a] pyrazine derivatives and their use for the prevention or treatment of neurological,psychiatric and metabolic disorders and diseases | |
PH12020500201A1 (en) | Pyrazolo and triazolo bicyclic compounds as jak kinase inhibitors | |
MX370390B (es) | Compuesto de 2-amino-6-fluoro-n-[5-fluoro-piridin-3-il]pirazolo[1, 5-a]pirimidin-3-carboxamida util como inhibidor de cinasa de ataxia telangiectasia mutada (atm) y rad3 relacionados (atr), su preparacion, diferentes formas solidas y sus derivados radiomarcados. | |
WO2011051342A8 (en) | IMIDAZO[1,2-b]PYRIDAZINE DERIVATIVES AND THEIR USE AS PDE10 INHIBITORS | |
MY196260A (en) | Small Molecule Inhibitors of the Jak Family Of Kinases | |
MX2018003351A (es) | Derivados de pirazolopirimidina como inhibidores de la btk para el tratramiento de cancer. | |
PH12014501355B1 (en) | Disubstituted benzothienyl-pyrrolotriazines and their use as fgfr kinase inhibitors | |
MY156727A (en) | N-(hetero)aryl-pyrrolidine derivatives of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines and pyrrol-3-yl-pyrrolo[2,3-d]pyrimidines as janus kinase inhibitors | |
TN2013000325A1 (en) | (1,2,4)triazolo[4,3-a]quinoxaline derivatives as inhibitors of phosphodiesterases | |
MX368162B (es) | Derivados de pirazolo[1,5-a]pirimidina sustituida con piperidina con actividad inhibidora sobre la replicacion del virus sincicial respiratorio (vsr). | |
MX2010006748A (es) | Pirazolo[1,5-a]pirimidinas utiles como inhibidores de jak2. | |
EA202091372A1 (ru) | Производное пирроло(пиразоло)пиримидина в качестве ингибитора lrrk2 | |
PH12018502168A1 (en) | 1,5-dihydro-4h-pyrazolo[3,4-d]pyrimidin-4-ones and 1,5-dihydro-4h-pyrazolo[4,3-c]pyridin-4-ones as pde1 inhibitors | |
MX362197B (es) | Derivados de imidazo[1,2-b]piridazina e imidazo[1,2-a]pirazina como inhibidores de la fosfodiesterasa 10; y el uso de los mismos en el tratamiento de trastornos neurológicos, psiquiátricos y metabólicos. | |
PH12018500796A1 (en) | Cyclic ether derivatives of pyrazolo[1,5-a] pyrimidine-3-carboxamide |